6 years ago

PredictImmune Closes €11 Million Series B to Expand Prognostic Test Pipeline

  • PredictImmune, a Cambridge-based startup, has raised €11 million in Series B funding to expand its pipeline of prognostic tests for chronic disorders.

      • ProblemHealthcare

      "Patients with immune-mediated diseases like IBD and lupus experience varying disease courses, making it difficult to determine the best treatment approach. This leads to trial-and-error medicine, delaying effective treatment and potentially causing unnecessary suffering."

      Solution

      "PredictImmune has developed a simple blood test that accurately predicts the severity and course of IBD, allowing doctors to choose the most appropriate treatment from the outset. This personalized approach eliminates the need for trial-and-error, leading to faster and more effective treatment for patients."

      Covered on